Company ProfilePremium

UMP Healthcare Holdings Limited

Company Profile Analysis

Ticker: 0722.HK聯合醫務集團有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
UMP Healthcare Holdings Limited - Company showcase

Year Founded & Workforce

1990

494 Employees

UMP Healthcare Holdings Limited logo

UMP Healthcare Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

UMP Healthcare Holdings Limited Overview

UMP Healthcare is a mid-sized, founder-controlled Hong Kong private healthcare platform whose economic engine is the design and administration of outpatient medical benefit plans for corporations and insurers, backed by an owned clinical estate and a contracted affiliate network of more than 1,000 service points across Hong Kong, Macau and the Chinese Mainland. Unlike pure clinic chains, UMP earns a large share of its revenue as a managed-care intermediary and third-party administrator (TPA), then captures internal referrals into its own general practice, specialist, dental, imaging (ProCare) and laboratory facilities. The group generated HK$717.0 million of revenue in FY2026, carries no bank debt and holds HK$331.3 million of cash, yet its returns have compressed for four consecutive years as immigration medical examination demand normalised, Hong Kong consumers shifted spending to Shenzhen and imaging investments depressed margins. FY2026 produced the first net loss in the period reviewed, driven by HK$96.8 million of non-cash impairments and Foshan start-up costs.


Company's own description (FY2026 annual results announcement)

In its FY2026 announcement, UMP describes itself as operating an integrated private healthcare platform that combines self-operated core clinical assets with selected strategic partnerships to create synergies across business lines, characterising this as an asset-light model that broadens service scope and market coverage while keeping capital commitments prudent and operations flexible. Management identifies three business lines: (1) Hong Kong & Macau Corporate Healthcare Solutions; (2) Hong Kong & Macau Clinical Services; and (3) Chinese Mainland Healthcare Services. The FY2025 Chairman's Statement framed the model as a "one-stop" ecosystem of Corporate Solutions, Medical Centres and Diagnostic Imaging in which corporate clients drive volume into the group's centres and diagnostics while clinical quality enhances the value of the corporate offering.

Business model and revenue model

Revenue model elementMechanismSegmentIndicative weight (FY2026)
Capitation plan contractsFixed per-member fees paid upfront by employers/insurers; UMP bears utilisation riskHK & Macau CorporatePart of 264.7 external revenue (split not disclosed)
Annual retainer contractsFixed annual fees, recognised over timeHK & Macau CorporatePart of 264.7 (split not disclosed)
Fee-for-service contractsBilled per treatment, typically due in 30–60 daysHK & Macau CorporatePart of 264.7 (split not disclosed)
TPA fees (hotline, pre-approval, claims)Administrative fees from insurers, including Mainland insurers' cross-border membersHK & Macau Corporate / Mainland—
Self-paid clinical servicesCash/card payment at point of service (GP, specialist, dental, imaging, lab, IME, physio, TCM)HK & Macau Clinical; Mainland412.8 (HK & Macau) + 39.5 (Mainland)
Government tenders and PPP programmesOutsourced imaging out-referrals, civil service dental, nurse clinic and allied-health pilotsHK & Macau Clinical—

UMP's revenue model is overwhelmingly service-based; there is no material product, licensing or software revenue. It can be decomposed as follows:

Revenue recognised at a point in time was HK$588.1 million in FY2026 (FY2025: 594.3) and over time HK$128.9 million (FY2025: 132.6), which approximates the split between transactional clinical revenue and contract/retainer revenue.

Value chain position

UMP sits at three points of the outpatient value chain simultaneously: (i) payer-side administrator/plan manager (designing plans, managing networks, adjudicating pre-approvals and claims for insurers and employers); (ii) network orchestrator (contracting affiliated doctors, dentists and auxiliary providers who are paid per plan member treated, recorded as "professional services expenses" of HK$262.6 million in FY2026, or 36.6% of revenue); and (iii) direct provider (owned medical centres, six integrated medical and advanced imaging centres and one central medical laboratory at 30 June 2026). Approximately HK$151.5 million of FY2026 segment revenue was inter-segment, largely clinical services sold to the corporate solutions business, demonstrating the internal referral loop.

Customer types and end-markets

Contract customers comprise insurance companies (covering policyholders or employees of policyholders) and corporations (covering employees and dependants); the website cites more than 2,000 insurer, multinational and blue-chip clients. The group discloses customer concentration: in 1H FY2026, "Customer A" contributed HK$23.3 million and "Customer B" HK$12.3 million of corporate-segment revenue (1H FY2025: 24.5 and 18.0), together roughly 9.7% of group revenue for the half. Related companies of Chow Tai Fook Enterprises (CTFE), a substantial shareholder, are also customers (trade receivables of HK$8.8 million due from them at 30 June 2026). Self-paid patients include walk-in Hong Kong residents, emigrants and students requiring immigration medical examinations, and Mainland residents seeking Hong Kong specialist care. End-markets are Hong Kong private outpatient care, Hong Kong employee benefits/group medical insurance administration, Macau corporate healthcare, and Mainland health check-ups and outpatient care (Beijing, Shanghai, Guangzhou, Foshan).

Independent characterisation

Analytically, UMP is best understood as a managed-care TPA with a captive provider arm, not a hospital or specialty clinic operator. The corporate solutions segment is the most profitable and stable earnings source (segment margin of 16.1% in FY2026), while the Hong Kong clinical segment carries most of the fixed cost (owned centres, imaging capex, leases) and has seen its margin collapse from 13.7% in FY2022 to 2.9% in FY2026. The Mainland business is sub-scale (5.5% of external revenue) and swung to a segment loss in FY2026 because of the Foshan pilot. The group's strategic pivot is to monetise its TPA know-how cross-border (Mainland insurers' members accessing Hong Kong care; Hong Kong plan members accessing Mainland tertiary hospitals) and to relocate back-office labour to Foshan.

Strategy

Stated strategy (paraphrased themes)

  • FY2025 Annual Report — four strategic pillars (Chairman's Statement): (1) Regional expansion, starting with a community healthcare centre in Guangdong and searching for partners/investments in other Mainland provinces; (2) Digital transformation (smart clinic systems, telemedicine, AI-assisted diagnostics, digital health platforms); (3) Preventive medicine and service diversification aligned with Hong Kong Government policy; (4) Talent development.

FY2025 Co-CEO joint priorities: deepening integration, investing in people, embracing innovation, expanding regionally.

1H FY2026 outlook: evolve from a traditional service operator into a holistic healthcare-ecosystem coordinator connecting patients, payers and providers; expand self-operated and affiliated centres while consolidating overlaps; deepen cross-boundary referral mechanisms.

FY2027 priorities (FY2026 announcement): (i) operational efficiency and cost control under an asset-light hybrid model; (ii) expansion of the Foshan back-office hub; (iii) technology-enabled innovation (UMP Member App, EPA penetration, eHealth integration, AI automation); (iv) network and service growth with emphasis on preventive care and Mainland commercial insurance/TPA; (v) specialist partnerships and new plan products (including concierge-style offerings); (vi) government collaboration (PPP programmes, tenders, community screening). Management also commits to aligning its roadmap with Hong Kong regulation and the strategic priorities of China's 15th national health plan.

Strategic initiatives register (last 24 months)

InitiativeTimingScopeStatus
Electronic Pre-Approval platformLaunched FY2025; broader rollout FY2026Digitises pre-approval/claims with insurersLive; penetration being deepened
New Clinic Management SystemLaunched end-FY2025; refined FY2026Paperless workflows, booking, drug and inventory managementLive
New corporate identityFY2025Rebrand at 35th anniversaryComplete
Mainland insurer TPA partnershipsFY2025–FY2026White-label TPA for Mainland insurers; cross-border members using Hong Kong networkSeveral partnerships signed (counterparties not named)
GBA back-office relocationFY2025–FY2026Data processing, claims, customer service, IT moved to FoshanExecuted; hub to expand in FY2027
Mainland IT team2,025Supports automation/digitalisationOperating
Foshan Community Healthcare Centre pilotEstablished 1H FY2026Primary care pilot aligned with national primary-care reformIn ramp-up; loss-making in FY2026
Guangzhou IME arrangement2,025Expand immigration medicals in South ChinaOperating
UMP Member App and corporate portal upgradeFY2026Member engagement and claims transparencyLaunched
Government tenders (imaging out-referrals, civil service dental)1H FY2026Diversify revenue, raise equipment utilisationWon
Nurse clinic and allied-health pilotsFY2026Community primary careOperating
Specialist partnership with 仁德醫健集團FY2026Expand specialist capacity without in-house hiringSigned
Tertiary hospital TPA cooperation (Shanghai East Hospital)FY2026Mainland TPA networkOperating
ProCare Physiotherapy consolidationSep 2026Unified physiotherapy brandComplete
AI use cases (claims document processing, workflow automation, imaging triage)FY2026–FY2027ProductivityEvaluation / early deployment

Sustainability and cost programmes

Environmental targets set in the FY2024 report: 5% intensity reduction by 2030 for GHG emissions, electricity, waste and water (Hong Kong operations); smart energy monitoring at the TST centre. Cost programmes are qualitative — workforce optimisation (employee costs -8.6% in FY2025), centre consolidation (right-of-use depreciation -13.6% in FY2025 and -8.4% in FY2026), procurement tightening and lower-rent relocations. No quantified cost-saving target has been published.

Medium-term financial targets / guidance

UMP does not publish quantitative financial guidance or medium-term targets. The most recent quantitative aspiration on record — 30 million online/offline users by 2025 (3 million in Hong Kong/Macau and 27 million in the Mainland), set in September 2020 — was effectively abandoned after the December 2021 disposal of the Mainland emerging business; the group reported roughly 1.3 million end users of corporate solutions in FY2025. Management's FY2026 outlook is described as cautiously optimistic.

Products & Services

Hong Kong & Macau Corporate Healthcare Solutions

OfferingDescription / capabilitiesTarget customerLaunch / latestPricing model
Corporate outpatient plans (capitation)Tailored employee outpatient benefit plans delivered through the UMP Network (>1,000 points of service)Employers (MNCs, blue chips, SMEs)Core since 1979/1990Fixed per-member fee, paid upfront
Annual retainer plansFixed-fee access/coverage arrangementsEmployersOngoingAnnual retainer, recognised over time
Fee-for-service schemesNetwork access billed per treatmentEmployers, insurersOngoingPer-treatment billing, 30–60-day terms
Third-party administration (TPA)Hotline support, pre-approval, claims processing, network management, utilisation analyticsInsurers and corporate clientsExtended to insurers from c.FY2020; expanded each yearAdministrative fees (not disclosed)
Electronic Pre-Approval (EPA) platformDigital pre-approval workflow linking outpatient, inpatient and claims administrationInsurers, plan membersLaunched FY2025; broader adoption FY2026Embedded in TPA fees
Individual-scheme TPA (B2B2C)Cashless, form-free outpatient treatment with network pre-approval for individual policyholdersInsurers (first client: FTLife, Oct 2022)FY2023—
Cross-border cashless networkAccess for Hong Kong plan members to designated Mainland clinics (~20 service points cited in FY2024) and tertiary hospitals for inpatient supportInsurers (first major user: AXA, Nov 2023), corporatesFY2024; expanded FY2026—
White-label TPA for Mainland insurersTPA integrated into Mainland insurers' health products for members seeking Hong Kong consultations, second opinions or elective careMainland insurersFY2025—
Modular "tailor-made" plansAdd-ons including mental health support and telehealth; pay-per-use optional servicesCorporates under cost pressure, SMEsFY2025–FY2026Modular pricing (not disclosed)
Corporate health managementPreventive screenings, vaccination programmes, occupational health, chronic-disease initiatives, wellness programmesCorporates, insurersOngoingPer programme
UMP Member AppAppointments, medical records, claims tracking, personalised health insightsPlan membersLaunched FY2026Free to members
Corporate client portalUpgraded self-service portal for HR/benefit administratorsCorporate clientsUpgraded FY2026Embedded
Concierge-style and value-added plan productsUnder explorationCorporates and individualsPlanned FY2027—

Hong Kong & Macau Clinical Healthcare Services

OfferingDescription / key capabilitiesTarget customerLaunch / latestPricing
General practice / family medicineFirst point of contact; network of UMP medical centres; GP revenue +1.7% in FY2026Self-paid patients, plan membersSince 1971/1990Per consultation
Specialist practiceMore than 20 specialties: cardiology, dermatology, endocrinology/diabetes, family medicine, gastroenterology & hepatology, general surgery, internal medicine, nephrology, neurology, neurosurgery, O&G, ophthalmology, orthopaedics, ENT, paediatrics, paediatric surgery, radiology, respiratory, rheumatology, urology; specialist revenue +3.4% in FY2026Self-paid, insured, referredExpanded via partnerships (e.g., 仁德醫健集團 in FY2026)Per consultation/procedure
Dental servicesPrimary (scaling, polishing) and secondary (crowns, bridges, orthodontics, implants, whitening); FY2026 dental revenue +7.4% pre-elimination, visits +9.7%Self-paid, plan members, civil service dental tenderOngoing; civil service dental tender won 1H FY2026Per treatment
ProCare Medical ImagingPET-CT, MRI, CT, ultrasound, mammography (incl. 3D), X-ray, bone densitometry; six integrated medical and advanced imaging centres; AI-assisted reads deployed; imaging revenue +4.3% in FY2026Self-paid, referred by specialists, insurers, government out-referralsPET-CT Admiralty Jun 2023; TST Feb 2023; Lee Garden Two Mar 2024Per scan (e.g., PET-CT HK$7,600 for Hong Kong Anti-Cancer Society members)
Central medical laboratoryHaematology, immunology, microbiology, molecular biology, cytology, histology, urinalysis, stool, allergy and drug testingInternal referrals, network doctorsOngoingPer test
Health check-ups / preventive medicineBody checks and screening packagesCorporates, self-paidOngoingPackages
Immigration Medical Examinations (IME)Visa medicals for emigrants/studentsSelf-paid emigrantsPeaked FY2022–FY2023; declining sincePer examination
UMP+ premium centresPreventive and lifestyle medicine; health checks, GP, specialist care adjacent to ProCare imaging; Central, Causeway Bay, Tsim Sha TsuiAffluent self-paid, corporate VIP membersBrand launched FY2024Premium pricing
ProCare PhysiotherapyAll physiotherapy centres rebranded under ProCareSelf-paid, plan membersConsolidated Sep 2026Per session
UMP Chinese Medicine CentreTCM centre in Jordan with cross-referrals; research MoU with HKBUSelf-paid, plan membersOpened Jul 2024Per consultation
SkinCentralDermatology and medical aesthetics; also operated at Humansa Victoria DocksideSelf-paidAcquired; Humansa agreement Oct 2022Per treatment
Oncology, day surgery and endoscopyAt One Chinachem Central with Pedder HealthcareSelf-paid, insuredJul 2022Per procedure
Cardiometabolic centreChronic-disease specialist centre at Wing On HouseSelf-paid, insured2,021Per consultation
Nutrition, nursing, nurse clinics, allied health pilotsCommunity-based primary care and government pilotsPublic programmes, self-paidFY2026Per service / programme fees
Government PPP and tender servicesImaging out-referrals, civil service dental, eHealth-linked GP programmes, vaccination subsidies, cancer screening supportHong Kong GovernmentExpanded FY2025–FY2026Tender pricing
Vaccination and video consultationsVaccines; telemedicineSelf-paid, plan membersOngoingPer service

Chinese Mainland Healthcare Services

OfferingDescriptionLocationLaunch / latest
Health check-up centresHealth assessments, including IMEBeijing, ShanghaiBeijing presence since c.2006; Shanghai Xintiandi from 2016
Selected outpatient servicesFamily medicine and selected specialties at owned clinicsBeijing, Shanghai, GBAOngoing
Guangzhou IME cooperative arrangementCooperative business arrangement supporting immigration medicals in South ChinaGuangzhou2,025
Foshan Community Healthcare Centre (pilot)25,300 sq ft, four storeys; floors 1–3 outpatient complex (15,780 sq ft) with preventive health assessment, clinical medicine, TCM, rehabilitation, dental, radiology, laboratory; floor 4 TPA office (9,515 sq ft)Nanhai District, FoshanEstablished 1H FY2026; operating through FY2026
Foshan shared-services hubHotline, claims administration, data processing, IT support, business developmentFoshanFunctions relocated during FY2026
Mainland TPA networkCooperation with tertiary hospitals including Shanghai East Hospital and international medical departmentsShanghai and othersFY2026

Financial Narrative

Income statement

Sources: annual results announcements FY2023, FY2024, FY2026; FY2025 Annual Report. FY2022 profit for the year includes HK$1.2 million from the discontinued GBA Healthcare operation.

Note: blank cells = not disclosed on a comparable basis. The company reported FY2022 EBITDA of HK$167.1 million under its old definition; it did not restate FY2022 to the new definition. FY2024 "adjusted EBITDA" of 78.4 is the FY2025 Annual Report's restated comparative (the FY2024 announcement itself cited core EBITDA of HK$66.8 million excluding only the HK$18.0 million profit-guarantee gain — a definitional discrepancy).

Revenue CAGR FY2022–FY2026: 1.9% per annum (HK$665.9 million to HK$717.0 million). FY2023–FY2026 CAGR: -0.5%.

Income statement commentary. Revenue growth stalled after FY2024. The FY2023 step-up (+9.2%) came from post-pandemic reopening, emigration-driven IME and imaging/specialist expansion; FY2024 (+2.9%) was supported by new imaging centres and corporate utilisation; FY2025 (-2.9%) and FY2026 (-1.4%) reflect IME normalisation and softer self-paid demand. Operating cost discipline was real but insufficient: employee costs fell 8.6% in FY2025 on workforce optimisation, and right-of-use depreciation declined from HK$71.0 million (FY2024) to HK$56.2 million (FY2026) through centre consolidation, yet professional services costs rose to 36.6% of revenue in FY2026 (35.4% in FY2025). The defining feature of FY2026 is the HK$82.0 million goodwill impairment (HK$76 million on the Hong Kong medical services CGU, HK$6 million on the Hong Kong dental CGU), HK$13.9 million impairment of an owned property and HK$0.9 million associate impairment, which together pushed "other expenses" to HK$167.5 million (23.4% of revenue). Excluding these, adjusted EBITDA still fell 20.7% to HK$75.2 million because of Foshan start-up costs and lower IME volumes. The effective tax charge of HK$8.0 million on a pre-tax loss reflects the non-deductibility of impairments (HK$16.8 million tax effect of non-deductible expenses).

Balance sheet

Note: FY2024 total assets are HK$1,106.4 million per the FY2024 announcement; the FY2025 Annual Report presents a slightly different comparative of HK$1,106.8 million (current assets restated to HK$489.5 million). The difference (HK$0.4 million) is immaterial and unexplained in the sources reviewed.

Balance sheet commentary. The balance sheet is conservatively financed: no bank borrowings or facilities in any year reviewed, a growing cash pile (HK$331.3 million, 33.4% of total assets) and net cash of HK$187.3 million even after including all lease liabilities and shareholder loans to subsidiaries. The quality of the asset base has shifted: goodwill and intangibles fell from 21.6% of total assets in FY2022 to 11.7% in FY2026 after the FY2026 write-down, materially de-risking future impairment exposure (remaining goodwill HK$76.3 million). PP&E rose sharply in FY2023 (imaging equipment purchased under August 2022 contracts) and has since been depreciated and impaired back to FY2022 levels. Equity attributable to owners fell 13.8% to HK$640.2 million in FY2026.

Cash flow

Blank cells: FY2026 cash-flow statement not yet published (annual report pending at research cut-off). Discrepancy: FY2025 capex is HK$12.3 million in the FY2025 Annual Report MD&A, HK$11.6 million in S&P data and HK$5.2 million in the FY2026 announcement's segment comparatives (which counts only PP&E additions and deposits by segment). FY2022–FY2023 dividends recognised exceed cash paid because part of the finals were settled in scrip (17.3 million shares in FY2022; 18.3 million shares in FY2023 at a deemed HK$0.78). The group has not conducted open-market buybacks for cancellation; purchases relate solely to the Share Award Scheme.

Cash flow commentary. Operating cash generation has been resilient at HK$150–190 million in FY2023–FY2025, well above reported net profit because of high non-cash D&A (HK$100–115 million per year). However, the true distributable cash flow after lease payments was thin until FY2025 (HK$14–19 million in FY2023–FY2024) because of the imaging capex cycle and HK$66–73 million annual lease outflows. FY2025's HK$77.7 million post-lease free cash flow — driven by capex collapsing to around HK$12 million — explains the 18.2% rise in cash despite an 85% payout. FY2026 cash still rose HK$28.5 million to HK$331.3 million despite the reported loss, confirming that the loss is predominantly non-cash.

Ratios

Direct costs = professional services expenses plus cost of inventories consumed. FY2026 interest coverage and ROIC are negative because of impairments; excluding the HK$96.8 million of FY2026 impairments, EBIT would have been approximately HK$33.9 million and interest coverage approximately 5.4x (analyst-calculated).

Ratio commentary. Returns have deteriorated in a straight line since FY2022: ROE fell from 10.3% to 4.2% before FY2026's loss, and ROIC on an underlying basis has settled around 5–6%, below any reasonable cost of equity for a HK$0.3 billion small-cap. Liquidity and solvency are not concerns — the current ratio of 2.11 and net cash position give ample headroom. Working capital is structurally near-neutral because the group pays affiliated providers on terms similar to or longer than its collection terms from contract customers (one-month standard credit, up to two months for major customers); receivables ageing deteriorated modestly in FY2026 (balances over three months rose to HK$9.1 million from HK$5.3 million).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment revenue (HKD Mn, before elimination)

Segment revenue (HKD Mn, before elimination)FY2022FY2023FY2024FY2025FY2026

HK & Macau Corporate Healthcare Solutions

237.0246.2255.8266.5266.3

HK & Macau Clinical Healthcare Services

500.4562.8583.1558.3562.0

Chinese Mainland Clinical Healthcare Services

37.644.743.139.040.2

Inter-segment elimination

-109.1-126.5-133.5-136.8-151.5

Group revenue

665.9727.2748.5726.9717.0

Segment external revenue (HKD Mn)

Segment external revenue (HKD Mn)FY2022FY2023FY2024FY2025FY2026

HK & Macau Corporate Healthcare Solutions

235.2244.7254.5264.8264.7

HK & Macau Clinical Healthcare Services

393.1437.8450.9423.2412.8

Chinese Mainland Clinical Healthcare Services

37.644.743.139.039.5

Contribution to group external revenue (%)

Contribution to group external revenue (%)FY2022FY2023FY2024FY2025FY2026

HK & Macau Corporate Healthcare Solutions

35.333.734.036.436.9

HK & Macau Clinical Healthcare Services

59.060.260.258.257.6

Chinese Mainland Clinical Healthcare Services

5.66.15.85.45.5

Revenue by Segment

Segment result (HKD Mn)FY2022FY2023FY2024FY2025FY2026

HK & Macau Corporate Healthcare Solutions

35.345.039.645.042.9

HK & Macau Clinical Healthcare Services

68.632.017.220.116.4

Chinese Mainland Clinical Healthcare Services

1.516.813.77.6-7.4

Total segment operating results

105.493.870.572.651.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment margin on pre-elimination revenue (%) (analyst-calculated)

Segment margin on pre-elimination revenue (%) (analyst-calculated)FY2022FY2023FY2024FY2025FY2026

HK & Macau Corporate Healthcare Solutions

14.918.315.516.916.1

HK & Macau Clinical Healthcare Services

13.75.73.03.62.9

Chinese Mainland Clinical Healthcare Services

4.137.631.819.4-18.5

Group total

13.611.08.08.46.0

YoY growth in segment revenue (%)

YoY growth in segment revenue (%)FY2023FY2024FY2025FY2026

HK & Macau Corporate Healthcare Solutions

3.93.94.2-0.1

HK & Macau Clinical Healthcare Services

12.53.6-4.30.7

Chinese Mainland Clinical Healthcare Services

18.8-3.5-9.53.0

Segment Assets & Liabilities

Item (HKD Mn)Corporate FY2025Corporate FY2026HK Clinical FY2025HK Clinical FY2026Mainland FY2025Mainland FY2026

Segment assets

245.8224.8287.3217.634.856.3

Segment liabilities

125.7120.8218.2205.918.050.5

Depreciation & amortisation

15.715.686.876.03.35.9

Capital expenditure

1.61.53.110.50.413.9

Operating Metrics (number)

Visits by segment (number)FY2022FY2023FY2024FY2025FY2026

HK & Macau corporate healthcare solution visits

849,405988,0911,287,5321,217,3111,102,512

HK & Macau clinical healthcare visits (self-paid)

255,609253,528228,850199,487183,324

Chinese Mainland clinical visits

28,64034,55835,43332,21635,683

Total visits

1,133,6541,276,1771,551,8151,449,0141,321,519

Income statement (HKD Mn)

Income statement (HKD Mn)FY2022FY2023FY2024FY2025FY2026

Revenue (continuing)

665.9727.2748.5726.9717.0

Other income and gains

21.419.635.914.212.6

Professional services expenses

-238.0-255.4-270.9-257.0-262.6

Employee benefit expense

-164.7-179.8-197.0-180.0-184.6

Property rental and related expenses

-11.1-14.0-16.6-15.4-15.4

Cost of inventories consumed

-37.6-45.2-56.2-56.7-59.9

Depreciation and amortisation

-78.6-103.9-113.8-105.8-97.5

Other expenses (incl. impairments)

-65.8-74.0-81.6-77.9-167.5

Finance cost

-3.9-5.7-6.9-7.3-6.3

Share of JV and associate results

-1.6-4.3-0.6-0.5-0.5

Profit before tax (continuing)

86.064.440.640.5-64.8

Income tax

-11.9-8.6-5.4-8.6-8.0

Profit for the year (incl. discontinued)

75.255.735.231.9-72.7

Profit attributable to owners

72.260.540.631.4-74.6

Non-controlling interests

3.1-4.7-5.40.51.9

Profitability measures (HKD Mn)

Profitability measures (HKD Mn)FY2022FY2023FY2024FY2025FY2026

Gross profit, analyst-derived (revenue less professional services and inventories)

390.3426.5421.4413.2394.5

EBIT, analyst-calculated (PBT + finance cost - interest income)

88.566.942.042.6-62.9

EBITDA, all D&A added back (analyst-calculated; equals company's pre-FY2024 definition)

167.1170.8155.8148.434.6

EBITDA, company definition (excludes ROU depreciation add-back)

—100.984.887.0-21.6

Adjusted EBITDA, company definition (ex impairments and one-offs)

——78.494.975.2

Total segment operating results

105.493.870.572.651.9

Pre-tax income

86.064.440.640.5-64.8

Net income attributable

72.260.540.631.4-74.6

Per-share data (HK cents)

Per-share data (HK cents)FY2022FY2023FY2024FY2025FY2026

EPS basic

9.347.655.083.98-9.42

EPS diluted

9.337.655.083.98-9.42

Dividends per share (interim + final)

4.504.703.303.302.80

Margins (%)

Margins (%)FY2022FY2023FY2024FY2025FY2026

Gross margin, analyst-derived

58.658.756.356.855.0

EBIT margin, analyst-calculated

13.39.25.65.9-8.8

EBITDA margin, all D&A (analyst-calculated)

25.123.520.820.44.8

EBITDA margin, company definition

—13.911.312.0-3.0

Adjusted EBITDA margin, company definition

——10.513.110.5

Net margin (profit for the year / revenue)

11.37.74.74.4-10.1

Balance Sheet

Balance sheet (HKD Mn, at 30 June)FY2022FY2023FY2024FY2025FY2026

Total assets

1,037.61,121.31,106.41,095.3990.7

Property, plant and equipment

141.5205.5212.9177.9141.5

Right-of-use assets

136.0107.9107.296.588.2

Goodwill

164.8164.8164.2156.676.3

Other intangible assets

59.948.237.937.940.1

Goodwill and intangibles combined

224.6213.0202.0194.5116.3

Trade receivables

81.4121.1131.0120.7125.4

Cash, bank balances and deposits

238.1290.5256.1302.8331.3

Total current assets

432.8495.5489.1536.8556.8

Total current liabilities

194.5271.1270.4269.1264.1

Net current assets (working capital)

238.3224.4218.7267.7292.7

Bank borrowings

0.00.00.00.00.0

Loans from non-controlling shareholders (current)

0.048.851.953.246.4

Lease liabilities, current

63.358.553.555.543.7

Lease liabilities, non-current

85.164.967.252.953.8

Total debt incl. leases and NCI loans (analyst-calculated)

148.3172.2172.6161.6144.0

Short-term debt (NCI loans + current leases)

63.3107.3105.4108.790.1

Long-term debt (non-current leases)

85.164.967.252.953.8

Net debt (total debt less cash; negative = net cash)

-89.8-118.3-83.5-141.2-187.3

Equity attributable to owners

698.7740.5725.9742.6640.2

Non-controlling interests

38.729.218.39.212.1

Total equity

737.3769.7744.3751.8652.3

Cash flow (HKD Mn)

Cash flow (HKD Mn)FY2022FY2023FY2024FY2025FY2026

Operating cash flow (S&P data)

110.9190.0148.8152.0—

Capital expenditure, company-reported

84.5109.357.212.325.9

Free cash flow (OCF less S&P capex)

26.480.791.5140.3—

Lease principal payments (S&P data)

55.066.473.062.6—

Free cash flow after leases (S&P data)

-28.614.318.577.7—

Dividends paid, cash (S&P data)

22.023.134.427.6—

Dividends recognised as distribution (company)

33.237.134.427.226.6

Share purchases for share award scheme (S&P data)

0.22.50.50.2—

Returns & Leverage Ratios (%) and Financial Ratios (x)

Ratios (analyst-calculated unless noted)FY2022FY2023FY2024FY2025FY2026

ROE, attributable profit / closing owners' equity (%) (company-reported basis)

10.38.25.64.2-11.7

ROA, profit for year / total assets (%)

7.35.03.22.9-7.3

ROIC, EBIT x (1-16.5%) / (equity + debt - cash) (%)

11.48.65.35.8-11.3

Current ratio (x) (company-reported)

2.231.831.811.992.11

Debt incl. leases and NCI loans / total equity (x)

0.200.220.230.210.22

Company gearing ratio, NCI loans / total equity (%)

0.06.37.07.17.1

Net debt / EBITDA all D&A (x)

-0.54-0.69-0.54-0.95-5.41

Interest coverage, EBIT / finance cost (x)

22.611.86.05.8-10.0

Asset turnover, revenue / total assets (x)

0.640.650.680.660.72

Days sales outstanding (days)

44.660.863.960.663.8

Days inventory on direct costs (days)

11.715.116.517.017.3

Days payables on direct costs (days)

51.877.884.671.780.7

Cash conversion cycle (days)

4.5-1.9-4.25.90.4

Geographic revenue (HKD Mn)

Geographic revenue (HKD Mn)FY2022FY2023FY2024FY2025FY2026

Hong Kong

609.9666.8690.2672.6663.0

Chinese Mainland

37.644.743.139.039.5

Macau

18.315.715.215.314.5

Total

665.9727.2748.5726.9717.0

Geographic revenue growth (%)

Geographic revenue growth (%)FY2023FY2024FY2025FY2026

Hong Kong

9.33.5-2.5-1.4

Chinese Mainland

18.8-3.5-9.51.2

Macau

-14.1-3.61.0-5.2

Geographic share of revenue (%)

Geographic share of revenue (%)FY2022FY2023FY2024FY2025FY2026

Hong Kong

91.691.792.292.592.5

Chinese Mainland

5.66.15.85.45.5

Macau

2.72.22.02.12.0

Segment (HKD Mn) Overview

Segment (HKD Mn)Hong KongChinese MainlandMacauTotal

Corporate Healthcare Solutions

253.00.011.7264.7

Clinical Healthcare Services

409.939.52.8452.3

Total

663.039.514.5717.0

Revenue by service type (HKD Mn)

Revenue by service type (HKD Mn)FY2022FY2023FY2024FY2025FY2026

Medical services

591.2649.1676.8657.1643.9

Dental services

74.778.171.769.973.0

Share Price & Returns

Reference pointPrice (HKD)Note

IPO (27 Nov 2015)

2.06

Listing price

25 Sep 2020

1.23

Post-FY2020 results intraday (Gelonghui)

Scrip dividend deemed price (FY2022 and FY2023 finals)

0.78

Company circulars Dec 2021 / Dec 2022

Jan–Mar 2025

0.42–0.46

ETNet quotes

52-week range (to Oct 2026)

0.315–0.50

StockAnalysis

Early Oct 2026

0.39–0.405

StockAnalysis / MarketScreener

Performance

Return

Source

Year-to-date 2026 (to 9 Oct 2026)

-13.8%

MarketScreener

1-year (market cap change)

approx. -17.5%

StockAnalysis

Since IPO

approx. -80% (excluding dividends)

Analyst-calculated vs HK$2.06

Valuation Multiples

MultipleUMPBasis

P/E (FY2026)

Not meaningful (loss)

EPS -9.42 cents

P/E (FY2025)

~10.1x

EPS 3.98 cents

P/B

~0.51x

Owners' equity HK$640.2 million

EV (incl. leases, NCI loans and NCI, less cash)

~HK$149 million

324 + 144.0 + 12.1 - 331.3

EV/Sales

~0.21x

FY2026 revenue 717.0

EV/Adjusted EBITDA (company definition)

~2.0x

75.2

EV/EBITDA (all D&A, ex impairments)

~1.1x

34.6 + 96.8 = 131.4

Dividend yield

~7.0%

HK2.80 cents

Dividend per share (HK cents)

Dividend per share (HK cents)FY2022FY2023FY2024FY2025FY2026

Interim

1.501.701.301.401.40

Final

3.003.002.001.901.40

Total

4.504.703.303.302.80

Analyst Conclusions

Management guidance

No numeric guidance. Management remains cautiously optimistic, prioritising cost control, scaling the Foshan hub, digital adoption, preventive care, specialist partnerships and government collaboration in FY2027, and characterising FY2026 impairments as non-recurring.

Consensus expectations

No reliable consensus exists (single broker; stale aggregator data). Implicitly, the market prices UMP at ~0.5x book and ~2x adjusted EBITDA, discounting continued low growth and limited capital reallocation.

Bull case

  1. Earnings rebound from a cleaner base: with HK$96.8 million of FY2026 impairments non-recurring and D&A falling (HK$97.5 million vs HK$113.8 million in FY2024), even flat adjusted EBITDA of ~HK$75 million could restore net profit of roughly HK$20–30 million (analyst estimate) as Foshan losses narrow.

  2. Cash-rich, deeply undervalued: net cash of HK$187.3 million represents ~58% of market cap; EV of ~HK$149 million for a business generating HK$150 million of annual operating cash flow (FY2023–FY2025) leaves substantial margin of safety, and a ~7% yield pays investors to wait.

  3. Cross-border TPA optionality: Mainland insurer white-label partnerships, AXA network and tertiary-hospital cooperation position UMP to monetise GBA healthcare integration with little capital.

Bear case

  1. Structural decline in Hong Kong clinical economics: segment margin of 2.9%, visits down 14.8% from peak and Shenzhen leakage suggest the owned-clinic estate may not earn its cost of capital; further impairments on the remaining HK$76.3 million goodwill or PP&E remain possible.

  2. Value trap governance: founder plus strategic shareholders control ~64%; free float is thin, institutional ownership ~0.2%, and history shows cash accumulating rather than being returned via buybacks; the dividend was cut 15% in FY2026.

  3. Mainland execution risk: the group exited its last Mainland expansion in 2021; the Foshan pilot already flipped the segment to a HK$7.4 million loss and could absorb further capital.

Catalysts and monitorables (next 12 months)

  • 2026 Annual Report (Oct 2026): FY2026 operating cash flow, director remuneration, impairment assumptions.

  • AGM on 20 Nov 2026: repurchase mandate, board composition votes.

  • 1H FY2027 interim results (expected late Feb 2027): Foshan losses, Mainland TPA revenue, adjusted EBITDA trend.

  • Any announced GBA M&A or partnership (stated exploration).

  • Hong Kong public healthcare fee reform effects on private volumes; government tender wins.

  • Corporate segment renewals and concentration (Customers A and B).

  • Further IME trends and cross-border dental leakage.

  • Insider purchases or any controlling-shareholder action (privatisation would be consistent with the valuation but is purely speculative and unannounced).

Concluding analyst verdict

UMP Healthcare is a financially conservative, cash-generative but strategically stalled Hong Kong managed-care and clinic operator. Its core asset — the corporate healthcare solutions and TPA franchise, generating roughly HK$43–45 million of segment profit at a mid-teens margin — remains intact and arguably undervalued. The problem is everything around it: the Hong Kong clinical estate has seen its margin fall from 13.7% to 2.9% in four years despite consolidation, immigration medicals are in structural retreat, and Hong Kong patients are migrating north for discretionary care. FY2026's HK$74.6 million loss is predominantly a non-cash recognition of what the share price had long implied — that the acquired Hong Kong medical and dental businesses were worth less than their carrying value.

The balance sheet is the decisive mitigant. With HK$331.3 million of cash, no bank debt and EV of only around HK$150 million, the market is ascribing almost no value to an operating business that produced around HK$150 million of operating cash flow annually in FY2023–FY2025. Downside appears limited by the cash and the dividend (≈7% yield), but upside requires either a demonstrable turnaround in Hong Kong clinical profitability, credible monetisation of the cross-border TPA strategy, or a capital-allocation event (special dividend, buyback, or corporate action by controlling shareholders). None is currently signalled. The Foshan pilot adds execution risk to a management team that previously retreated from the Mainland.

On balance, UMP screens as a deep-value, low-liquidity special situation rather than a growth or quality compounder. Key data points to verify upon publication of the 2026 Annual Report are FY2026 operating cash flow, impairment-test headroom on remaining goodwill, and director remuneration relative to shareholder returns.


Prepared from public sources available to 17 October 2026: UMP Healthcare HKEX filings (FY2023, FY2024 and FY2026 annual results announcements; FY2025 Annual Report; 1H FY2026 interim results announcement), company website and press releases, SFC notice (Apr 2017), ETNet, StockAnalysis/S&P Global Market Intelligence, MarketScreener, Yahoo Finance, Simply Wall St, TipRanks, ETNet/AASTOCKS/TVB/Tencent news coverage, and peer company filings (Human Health, Town Health, EC Healthcare). Figures marked analyst-calculated are the author's derivations; no figures were estimated where disclosure was absent.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure / background (as disclosed)Committees

Dr SUN Yiu Kwong (孫耀江)

Chairman, Executive Director

Founder; opened first clinic 1971, founded UMP 1990; Chairman and CEO until retiring as CEO on 1 Jan 2023; controlling shareholder

Chairman, Nomination Committee

Dr SUN Man Kin, Michael (孫文堅)

Vice Chairman and Co-CEO, Executive Director

Co-CEO since 1 Jan 2023; leads clinical excellence, diagnostics and technology

—

Ms KWOK Cheuk Kwan, Jacquen (郭卓君)

Co-CEO, Executive Director

With UMP for more than three decades; leads corporate solutions/managed care, strategy, M&A exploration; authorised representative

Nomination Committee (from 13 Jun 2025)

Mr TSANG On Yip, Patrick, BBS (曾安業)

Executive Director

Senior executive of Chow Tai Fook Enterprises (described as CTFE CEO in the FY2024 announcement and as a CTFE director in 2026 filings)

Remuneration Committee

Dr LEE Pak Cheung, Patrick (李柏祥)

Executive Director

——

Ms CHENG Chi Man, Sonia (鄭志雯)

Non-executive Director

——

Mr LEE Luen Wai, John, BBS JP (李聯偉)

Independent Non-executive Director

Long-serving INED

Chairman, Audit Committee; Remuneration and Nomination Committees

Mr YEUNG Tak Bun, BBS JP (楊德斌)

Independent Non-executive Director

Joined board c.FY2024 (replacing Mr Yeung Wing Sun, Mike)

Audit Committee; Nomination Committee (from 13 Jun 2025)

Mrs CHAN KUNG Wai Ying, Amy (陳龔偉瑩)

Independent Non-executive Director

Replaced Dr Li Kwok Tung, Donald, GBS JP (former Remuneration Committee chair) between Oct 2025 and Feb 2026

Audit Committee

Board & Management Changes

DateChangeContext

1 Jan 2023

Dr Sun Yiu Kwong retires as CEO; Dr Michael Sun and Ms Jacquen Kwok become Co-CEOs

Succession; separation of Chair/CEO

21 Sep 2023

Dr Lee Kar Chung, Felix re-designated from Executive to Non-executive Director

CTFE nominee

FY2024

INEDs Mr Yeung Wing Sun, Mike and Mr Chau Chit, Jeremy leave; Mr Yeung Tak Bun joins

Board refresh

13 Jun 2025

Ms Kwok and Mr Yeung Tak Bun appointed to Nomination Committee

Gender diversity on committee

—

Ms Cheng Chi Man, Sonia replaces Dr Felix Lee as NED; Mrs Chan Kung Wai Ying, Amy replaces Dr Donald Li as INED; Tong Mo Ting replaces Cheung Chi Wah, Patrick as company secretary

Board and secretarial refresh

Major Shareholders

HolderShares% of issuedDate of recordSource

Dr Sun Yiu Kwong and associates

300,226,98937.02

30 Jun 2025

ETNet (company disclosures)

Chow Tai Fook (Holding) Limited (via CTFE / Healthcare Ventures Holdings)

123,764,02715.26

30 Jun 2025

ETNet

China Resources Medical Holdings Company Limited (1515.HK)

91,803,00011.32

4 Feb 2026

ETNet

Institutional investors

~1.5 million

~0.19

2025

Simply Wall St

Public / other

balance

~36

—

Derived

Competitive Landscape

Key Competitors

CompetitorListingOverlap with UMPLatest revenue (HKD Mn) and periodRelative positioning

EC Healthcare (醫思健康)

2138.HK

Hong Kong non-hospital medical services, imaging, specialists, dental, check-ups

3770.2 (FY to 31 Mar 2026, -8.9%); net loss 412.9

Largest non-hospital group; consumer/aesthetics-led; heavier losses

Town Health International Medical Group (康健國際)

3886.HK

Hong Kong GP/specialist network, corporate healthcare schemes, Mainland healthcare

1785.6 (FY Dec 2025, -2.6%)

Larger, diversified (incl. property); direct rival in corporate schemes

Human Health Holdings (盈健醫療)

1419.HK

Hong Kong GP, specialist and dental networks; corporate/insurance contracts; also a partner of UMP

644.4 (FY Jun 2025, +9.1%); 342.4 (1H FY2026, +8.4%)

Similar size; growing faster, especially dental

Quality HealthCare Medical Services

Private

Corporate healthcare schemes, clinics, TPA

—

Long-established direct rival in managed outpatient care

Bupa (Asia) / Bupa Hong Kong

Private (insurer)

Group medical insurance with own network administration

—

Payer-integrated competitor and potential client

Private hospitals (e.g., Hong Kong Sanatorium & Hospital, Gleneagles Hong Kong, CUHK Medical Centre)

Private / IHH (Gleneagles)

Imaging, check-ups, specialist outpatient

—

Premium imaging/check-up competitors

Specialist imaging and lab operators (e.g., Pedder Healthcare-affiliated centres, standalone imaging groups)

Mostly private

Imaging, laboratory

—

Fragmented; price competition cited by UMP

Shenzhen private dental and medical providers

Mainland

Cross-border leakage of Hong Kong self-paid dental and elective demand

Not applicable

Structural substitute cited by UMP since FY2024

iKang Healthcare Group

Private (formerly NASDAQ)

Mainland health check-ups

—

Mainland check-up leader; UMP is sub-scale

Meinian Onehealth Healthcare

002044.SZ

Mainland health check-ups

—

Mainland check-up leader

United Family Healthcare (New Frontier/NewMed)

Private

Premium international outpatient in Beijing/Shanghai/GBA

—

Competes for expatriate/insured patients in Mainland

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricUMP (FY Jun 2026)Human Health (FY Jun 2025)Town Health (FY Dec 2025)EC Healthcare (FY Mar 2026)

Revenue (HKD Mn)

717.0644.41,785.63,770.2

Revenue growth (%)

-1.49.1-2.6-8.9

Adjusted EBITDA margin (%)

10.5——7.4

Net result (HKD Mn)

-72.7——-412.9

Company Snapshot

494

Employees

$41M

Market Cap

1990

Founded

Des Voeux Road Central, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Net cash balance sheet: HK$331.3 million cash, zero bank borrowings, net cash of HK$187.3 million after all leases and NCI loans (FY2026 announcement).
  • Resilient corporate segment: revenue held at HK$266.3 million in FY2026 with a 16.1% segment margin, the most profitable business line.
  • Strong pre-lease operating cash generation: OCF of HK$148.8–190.0 million in FY2023–FY2025 (S&P data), consistently 3–5x reported net profit.
  • Integrated referral model: inter-segment revenue rose 10.7% to HK$151.5 million in FY2026, showing captured internal demand.
  • Dividend track record: cash dividends paid every year since listing; FY2026 payout of HK2.80 cents despite a loss, implying ~7% yield.
  • Strategic shareholders: CTFE (15.26%) and China Resources Medical (11.32%) alongside founder (37.02%).
  • Digitised administration: EPA platform, integrated CMS and UMP Member App live (FY2025–FY2026).

Weaknesses

  • Declining returns: ROE fell from 10.3% (FY2022) to 4.2% (FY2025) and -11.7% (FY2026).
  • Hong Kong clinical margin collapse: segment margin 13.7% (FY2022) to 2.9% (FY2026).
  • Acquisition write-downs: goodwill impairments of HK$20.0 million (FY2021), HK$0.6 million (FY2024), HK$7.6 million (FY2025) and HK$82.0 million (FY2026) indicate overpayment for past acquisitions.
  • Volume decline: total visits down 14.8% from FY2024 peak (1.55 million to 1.32 million).
  • Customer concentration: two customers ≈HK$35.6 million of 1H FY2026 revenue.
  • High professional-services cost share: 36.6% of revenue in FY2026, limiting operating leverage.
  • Low staff training intensity: only 28% of employees trained, average 0.5 hours (FY2025 ESG report), with 27.1% turnover.

Opportunities

  • Mainland insurer TPA: white-label partnerships signed in FY2025; management expects high-margin revenue as products gain traction.
  • GBA labour arbitrage: Foshan hub centralising hotline, claims and IT can structurally lower TPA cost per claim.
  • Hong Kong primary care policy: chronic disease co-care, vaccination subsidies, cancer screening and government tenders (imaging out-referrals and civil service dental won in 1H FY2026).
  • Public fee reform: higher public hospital charges improve private price competitiveness (cited in FY2025 AR and 1H FY2026).
  • Specialist partnerships: asset-light specialist expansion (仁德醫健集團 collaboration) without fixed hiring costs.
  • AI automation: claims document processing and imaging triage can reduce manual workload.
  • Balance-sheet optionality: HK$331 million cash available for bolt-on M&A in the GBA (stated exploration).

Threats

  • Cross-border leakage: Hong Kong dental and elective demand migrating to Shenzhen (FY2024–FY2026 MD&As).
  • Structural IME decline: cited as the primary cause of FY2026 revenue decline.
  • Larger, distressed competitors pricing aggressively: EC Healthcare revenue -8.9% and net loss HK$412.9 million (FY Mar 2026) may intensify discounting.
  • Corporate headcount cuts: affecting enrolment-based plans (FY2025–FY2026).
  • Regulatory tightening: Cap. 633 compliance costs; Mainland policy shifts.
  • Geopolitical tension and RMB volatility: affect Mainland IME demand and RMB-denominated operations; no hedging in place.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
8 Apr 2025Executive Director Dr Lee Pak Cheung buys 40,000 shares at HK$0.39Insider confidence signal (small)
13 Jun 2025Ms Jacquen Kwok and Mr Yeung Tak Bun appointed to Nomination CommitteeGovernance/diversity compliance
FY2025Partnerships with several Mainland insurers for white-label TPANew cross-border revenue channel
FY2025EPA platform and paperless Clinic Management System launched; new corporate identityDigital transformation milestone
2025Guangzhou cooperative IME arrangement startedDiversifies IME geography
2025Mainland IT team established; back-office functions begin moving to GBALabour-cost arbitrage
17 Sep 2025FY2025 results: revenue HK$726.9 million (-2.9%); attributable profit HK$31.4 million (-22.6%); adjusted EBITDA +21.1% to HK$94.9 millionCost efficiency offsets revenue decline
17 Sep 2025Final dividend HK1.90 cents proposed (FY HK3.30 cents; ~85% payout)Shareholder return despite lower profit
27 Oct 2025FY2025 Annual Report and ESG report published (35th/10th anniversary)Four strategic pillars announced
21 Nov 2025AGM approves FY2025 final dividendRoutine
Oct 2025–Feb 2026Board refresh: Ms Cheng Chi Man, Sonia (NED) and Mrs Chan Kung Wai Ying, Amy (INED) join; Dr Felix Lee and Dr Donald Li depart; new company secretary Tong Mo Ting–
2H CY2025Four-storey Foshan integrated healthcare centre and TPA office establishedFirst direct-operated Mainland site post-2022
1H FY2026Tenders won for imaging out-referrals and civil service dental servicesPublic-sector revenue diversification
9 Jan 2026FY2025 final dividend paidRoutine
25 Feb 20261H FY2026 results: revenue HK$367.5 million (-1.0%); attributable profit HK$18.4 million (+2.5%); segment results +16.7%Underlying profitability improved in 1H
25 Feb 2026Interim dividend HK1.40 cents declaredMaintained
23 Mar 20262025/2026 Interim Report publishedRoutine
15 Apr 2026Interim dividend paidRoutine
Mar–May 2026Monthly returns: 810.96 million shares, no capital movementsStable capital base
Aug 2026Monthly return shows 2.40 million legacy options lapsingReduces overhang (10.2 million Post-IPO options outstanding at 30 Jun 2026)
FY2026UMP Member App launched; corporate portal upgradedDigital engagement
FY2026Hotline, IT and business development functions relocated to Foshan hubCost base restructuring
FY2026Specialist collaboration with 仁德醫健集團; TPA cooperation with Shanghai East HospitalAsset-light network expansion
4 Sep 2026Profit warning: expected FY2026 net loss ~HK$76 million (vs ~HK$32 million profit) due to impairments and Foshan start-up costsMajor negative earnings revision
9 Sep 2026Physiotherapy consolidated under ProCare PhysiotherapyBrand rationalisation
Sep 2026Board meeting notice for 24 Sep resultsRoutine
24 Sep 2026FY2026 results: revenue HK$717.0 million (-1.4%); loss attributable HK$74.6 million; goodwill impairment HK$82.0 million; PP&E impairment HK$13.9 million; adjusted EBITDA HK$75.2 million (-20.7%)First loss in five years; balance-sheet clean-up
24 Sep 2026Final dividend cut to HK1.40 cents (FY total HK2.80 cents, -15.2%); payable 8 Jan 2027, record date 11 Dec 2026Dividend maintained in cash despite loss
20 Nov 2026 (scheduled)2026 AGM at 2:30 p.m.; register closed 17–20 Nov 2026Upcoming governance event
Oct 2026Share price trades at HK$0.39–0.405, near 52-week range midpoint (HK$0.315–0.50); YTD -13.8% (to 9 Oct 2026)Market reaction muted given low expectations

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

10 charts
Income Statement: Revenue & Gross Profit: Revenue (continuing) rose from HKD 665.9 Mn in FY2022 to HKD 717 Mn in FY2026.
UMP Healthcare Holdings Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue (continuing)665.9727.2748.5726.9717
Cost of inventories consumed-37.6-45.2-56.2-56.7-59.9
Gross profit, analyst- (revenue less professional services and inventories)390.3426.5421.4413.2394.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.